Clinical Trial Update: Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies [Phase 2]

View source ↗

Summary

Phase 2 trial of Entospletinib plus Idelalisib in adults with relapsed or refractory hematologic malignancies was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Indolent Non-hodgkin Lymphoma
• Mantle Cell Lymphoma

Drugs mentioned

• Entospletinib (entospletinib)
• Idelalisib (idelalisib)

Snippet

Sponsor: Gilead Sciences | Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2020-06-02